Motor Progression in Early-Stage Parkinson's Disease: A Clinical Prediction Model and the Role of Cerebrospinal Fluid Biomarkers
Background: The substantial heterogeneity of clinical symptoms and lack of reliable progression markers in Parkinson's disease (PD) present a major challenge in predicting accurate progression and prognoses. Increasing evidence indicates that each component of the neurovascular unit (NVU) and b...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-01-01
|
Series: | Frontiers in Aging Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fnagi.2020.627199/full |
id |
doaj-aab560c3a8bd496ba2653ab39d93f102 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ling-Yan Ma Ling-Yan Ma Yu Tian Chang-Rong Pan Zhong-Lue Chen Yun Ling Kang Ren Jing-Song Li Tao Feng Tao Feng Tao Feng |
spellingShingle |
Ling-Yan Ma Ling-Yan Ma Yu Tian Chang-Rong Pan Zhong-Lue Chen Yun Ling Kang Ren Jing-Song Li Tao Feng Tao Feng Tao Feng Motor Progression in Early-Stage Parkinson's Disease: A Clinical Prediction Model and the Role of Cerebrospinal Fluid Biomarkers Frontiers in Aging Neuroscience Parksinon's disease motor progression predictive model Parkinson's progression markers initiative machine learning |
author_facet |
Ling-Yan Ma Ling-Yan Ma Yu Tian Chang-Rong Pan Zhong-Lue Chen Yun Ling Kang Ren Jing-Song Li Tao Feng Tao Feng Tao Feng |
author_sort |
Ling-Yan Ma |
title |
Motor Progression in Early-Stage Parkinson's Disease: A Clinical Prediction Model and the Role of Cerebrospinal Fluid Biomarkers |
title_short |
Motor Progression in Early-Stage Parkinson's Disease: A Clinical Prediction Model and the Role of Cerebrospinal Fluid Biomarkers |
title_full |
Motor Progression in Early-Stage Parkinson's Disease: A Clinical Prediction Model and the Role of Cerebrospinal Fluid Biomarkers |
title_fullStr |
Motor Progression in Early-Stage Parkinson's Disease: A Clinical Prediction Model and the Role of Cerebrospinal Fluid Biomarkers |
title_full_unstemmed |
Motor Progression in Early-Stage Parkinson's Disease: A Clinical Prediction Model and the Role of Cerebrospinal Fluid Biomarkers |
title_sort |
motor progression in early-stage parkinson's disease: a clinical prediction model and the role of cerebrospinal fluid biomarkers |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Aging Neuroscience |
issn |
1663-4365 |
publishDate |
2021-01-01 |
description |
Background: The substantial heterogeneity of clinical symptoms and lack of reliable progression markers in Parkinson's disease (PD) present a major challenge in predicting accurate progression and prognoses. Increasing evidence indicates that each component of the neurovascular unit (NVU) and blood-brain barrier (BBB) disruption may take part in many neurodegenerative diseases. Since some portions of CSF are eliminated along the neurovascular unit and across the BBB, disturbing the pathways may result in changes of these substances.Methods: Four hundred seventy-four participants from the Parkinson's Progression Markers Initiative (PPMI) study (NCT01141023) were included in the study. Thirty-six initial features, including general information, brief clinical characteristics and the current year's classical scale scores, were used to build five regression models to predict PD motor progression represented by the coming year's Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III score after redundancy removal and recursive feature elimination (RFE)-based feature selection. Then, a threshold range was added to the predicted value for more convenient model application. Finally, we evaluated the CSF and blood biomarkers' influence on the disease progression model.Results: Eight hundred forty-nine cases were included in the study. The adjusted R2 values of three different categories of regression model, linear, Bayesian and ensemble, all reached 0.75. Models of the same category shared similar feature combinations. The common features selected among the categories were the MDS-UPDRS Part III score, Montreal Cognitive Assessment (MOCA) and Rapid Eye Movement Sleep Behavior Disorder Questionnaire (RBDSQ) score. It can be seen more intuitively that the model can achieve certain prediction effect through threshold range. Biomarkers had no significant impact on the progression model within the data in the study.Conclusions: By using machine learning and routinely gathered assessments from the current year, we developed multiple dynamic models to predict the following year's motor progression in the early stage of PD. These methods will allow clinicians to tailor medical management to the individual and identify at-risk patients for future clinical trials examining disease-modifying therapies. |
topic |
Parksinon's disease motor progression predictive model Parkinson's progression markers initiative machine learning |
url |
https://www.frontiersin.org/articles/10.3389/fnagi.2020.627199/full |
work_keys_str_mv |
AT lingyanma motorprogressioninearlystageparkinsonsdiseaseaclinicalpredictionmodelandtheroleofcerebrospinalfluidbiomarkers AT lingyanma motorprogressioninearlystageparkinsonsdiseaseaclinicalpredictionmodelandtheroleofcerebrospinalfluidbiomarkers AT yutian motorprogressioninearlystageparkinsonsdiseaseaclinicalpredictionmodelandtheroleofcerebrospinalfluidbiomarkers AT changrongpan motorprogressioninearlystageparkinsonsdiseaseaclinicalpredictionmodelandtheroleofcerebrospinalfluidbiomarkers AT zhongluechen motorprogressioninearlystageparkinsonsdiseaseaclinicalpredictionmodelandtheroleofcerebrospinalfluidbiomarkers AT yunling motorprogressioninearlystageparkinsonsdiseaseaclinicalpredictionmodelandtheroleofcerebrospinalfluidbiomarkers AT kangren motorprogressioninearlystageparkinsonsdiseaseaclinicalpredictionmodelandtheroleofcerebrospinalfluidbiomarkers AT jingsongli motorprogressioninearlystageparkinsonsdiseaseaclinicalpredictionmodelandtheroleofcerebrospinalfluidbiomarkers AT taofeng motorprogressioninearlystageparkinsonsdiseaseaclinicalpredictionmodelandtheroleofcerebrospinalfluidbiomarkers AT taofeng motorprogressioninearlystageparkinsonsdiseaseaclinicalpredictionmodelandtheroleofcerebrospinalfluidbiomarkers AT taofeng motorprogressioninearlystageparkinsonsdiseaseaclinicalpredictionmodelandtheroleofcerebrospinalfluidbiomarkers |
_version_ |
1724324620508594176 |
spelling |
doaj-aab560c3a8bd496ba2653ab39d93f1022021-01-25T05:50:39ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652021-01-011210.3389/fnagi.2020.627199627199Motor Progression in Early-Stage Parkinson's Disease: A Clinical Prediction Model and the Role of Cerebrospinal Fluid BiomarkersLing-Yan Ma0Ling-Yan Ma1Yu Tian2Chang-Rong Pan3Zhong-Lue Chen4Yun Ling5Kang Ren6Jing-Song Li7Tao Feng8Tao Feng9Tao Feng10Department of Neurology, Center for Movement Disorders, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaEngineering Research Center of Electronic Medical Record (EMR) and Intelligent Expert System, College of Biomedical Engineering and Instrument Science, Zhejiang University, Ministry of Education, Hangzhou, ChinaEngineering Research Center of Electronic Medical Record (EMR) and Intelligent Expert System, College of Biomedical Engineering and Instrument Science, Zhejiang University, Ministry of Education, Hangzhou, ChinaGyenno Science Co. Ltd., Shenzhen, ChinaGyenno Science Co. Ltd., Shenzhen, ChinaGyenno Science Co. Ltd., Shenzhen, ChinaEngineering Research Center of Electronic Medical Record (EMR) and Intelligent Expert System, College of Biomedical Engineering and Instrument Science, Zhejiang University, Ministry of Education, Hangzhou, ChinaDepartment of Neurology, Center for Movement Disorders, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaParkinson's Disease Center, Beijing Institute for Brain Disorders, Beijing, ChinaBackground: The substantial heterogeneity of clinical symptoms and lack of reliable progression markers in Parkinson's disease (PD) present a major challenge in predicting accurate progression and prognoses. Increasing evidence indicates that each component of the neurovascular unit (NVU) and blood-brain barrier (BBB) disruption may take part in many neurodegenerative diseases. Since some portions of CSF are eliminated along the neurovascular unit and across the BBB, disturbing the pathways may result in changes of these substances.Methods: Four hundred seventy-four participants from the Parkinson's Progression Markers Initiative (PPMI) study (NCT01141023) were included in the study. Thirty-six initial features, including general information, brief clinical characteristics and the current year's classical scale scores, were used to build five regression models to predict PD motor progression represented by the coming year's Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III score after redundancy removal and recursive feature elimination (RFE)-based feature selection. Then, a threshold range was added to the predicted value for more convenient model application. Finally, we evaluated the CSF and blood biomarkers' influence on the disease progression model.Results: Eight hundred forty-nine cases were included in the study. The adjusted R2 values of three different categories of regression model, linear, Bayesian and ensemble, all reached 0.75. Models of the same category shared similar feature combinations. The common features selected among the categories were the MDS-UPDRS Part III score, Montreal Cognitive Assessment (MOCA) and Rapid Eye Movement Sleep Behavior Disorder Questionnaire (RBDSQ) score. It can be seen more intuitively that the model can achieve certain prediction effect through threshold range. Biomarkers had no significant impact on the progression model within the data in the study.Conclusions: By using machine learning and routinely gathered assessments from the current year, we developed multiple dynamic models to predict the following year's motor progression in the early stage of PD. These methods will allow clinicians to tailor medical management to the individual and identify at-risk patients for future clinical trials examining disease-modifying therapies.https://www.frontiersin.org/articles/10.3389/fnagi.2020.627199/fullParksinon's diseasemotor progressionpredictive modelParkinson's progression markers initiativemachine learning |